Targeted Therapies for Cancer
ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.
Product Pipeline
Our IMGN901 is now in Phase II testing for SCLC
Read more about it...We have several scientific presentations on our product candidates at AACR.
Click here to learn more...
Our TAP Technology
Trastuzumab emtansine (T-DM1) met PFS endpoint in
EMILIA Phase III trial